Interventions for treating psoriatic arthritis

G. Jones, M. Crotty, P. Brooks

Research output: Contribution to journalReview articlepeer-review

92 Citations (Scopus)


It has been estimated that arthritis occurs in 5‐7 % of those with psoriasis, which can cause substantial disability in some patients.

The objective was to assess the benefits of the treatment [sulfasalazine, auranofin, etretinate, fumaric acid, IMI gold, azathioprine, methotrexate] for psoriatic arthritis and to assess the side effects. Parenteral methotrexate and sulfasalazine resulted in important benefit in over half the patients for psoriatic arthritis in these studies. There was insufficient data to evaluate other therapies and to examine toxicity. Further multicentre trials are required to establish the efficacy of azathioprine, oral methotrexate, etretinate, and colchicine.
Original languageEnglish
Article numberCD000212
JournalCochrane Database of Systematic Reviews
Issue number2
Publication statusPublished - 24 Jul 2000
Externally publishedYes


  • Arthritis
  • psoriasis
  • randomised controlled trial


Dive into the research topics of 'Interventions for treating psoriatic arthritis'. Together they form a unique fingerprint.

Cite this